Relation of FGFR2 genetic polymorphisms to the association between oral contraceptive use and the risk of breast cancer in Chinese women.

The fibroblast growth factor receptor 2 gene (FGFR2) has been associated with the risk of breast cancer in multiple ethnic populations, and its effect has been suggested to be hormone-dependent. A large, 2-stage, population-based case-control study was conducted in urban Shanghai, China, during the periods of 1996-1998 and 2002-2005. Exposure and genotyping information from 2,073 patients with breast cancer and 2,084 age-matched population controls was available for evaluation of the interactions between FGFR2 polymorphisms and exogenous estrogen exposure in the development of breast cancer. A logistic regression model was used to compute adjusted odds ratios and 95% confidence intervals. Of 20 genotyped and 25 imputed single nucleotide polymorphisms (SNPs), 22 were significantly associated with breast cancer. Three genotyped SNPs in close linkage disequilibrium, rs2303568, rs3135730, and rs1078806, and an imputed SNP of rs755793 in complete linkage disequilibrium with other 8 SNPs were observed to interact significantly with oral contraceptive (OC) use. The SNP-cancer association was evident only among OC users, and the OC use was only associated with the risk of breast cancer among carriers of these minor alleles at these loci. These findings suggest that genetic variants in FGFR2 may modify the role of OC use in causing breast cancer in Chinese women.

[1]  Mark Daly,et al.  Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..

[2]  Chen-Yang Shen,et al.  Cytochrome P4501A1 polymorphism as a susceptibility factor for breast cancer in postmenopausal Chinese women in Taiwan , 1999, British Journal of Cancer.

[3]  D. Givol,et al.  Complexity of FGF receptors: genetic basis for structural diversity and functional specificity , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[4]  N. Rothman,et al.  Urinary polyphenols and breast cancer risk: results from the Shanghai Women’s Health Study , 2010, Breast Cancer Research and Treatment.

[5]  S. Kuriyama,et al.  Reproductive factors, exogenous female hormone use and breast cancer risk in Japanese: the Miyagi Cohort Study , 2009, Cancer Causes & Control.

[6]  C. Matthews,et al.  Lifetime physical activity and breast cancer risk in the Shanghai Breast Cancer Study , 2001, British Journal of Cancer.

[7]  X. Shu,et al.  Use of oral contraceptives, intrauterine devices and tubal sterilization and cancer risk in a large prospective study, from 1996 to 2006 , 2009, International journal of cancer.

[8]  D. Cox,et al.  Variation in the FGFR2 Gene and the Effects of Postmenopausal Hormone Therapy on Invasive Breast Cancer , 2009, Cancer Epidemiology, Biomarkers & Prevention.

[9]  M. Pike,et al.  Breast cancer and oral contraceptive use in Asian-American women. , 1999, American journal of epidemiology.

[10]  R. Langer,et al.  Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. , 2003, JAMA.

[11]  K. Matsuo,et al.  FGFR2 intronic polymorphisms interact with reproductive risk factors of breast cancer: Results of a case control study in Japan , 2009, International journal of cancer.

[12]  J. Yager,et al.  Endogenous estrogens as carcinogens through metabolic activation. , 2000, Journal of the National Cancer Institute. Monographs.

[13]  Francesmary Modugno,et al.  Oral contraceptive use as a risk factor for premenopausal breast cancer: a meta-analysis. , 2006, Mayo Clinic proceedings.

[14]  Julian Peto,et al.  Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer , 1997, The Lancet.

[15]  S. Gabriel,et al.  The Structure of Haplotype Blocks in the Human Genome , 2002, Science.

[16]  J. Haines,et al.  Genome-wide association study identifies a novel breast cancer susceptibility locus at 6q25.1 , 2009, Nature Genetics.

[17]  Julian Peto,et al.  Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies , 1996, The Lancet.

[18]  K. Straif,et al.  Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment. , 2005, The Lancet. Oncology.

[19]  P. Gregersen,et al.  Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33 , 2008, Proceedings of the National Academy of Sciences.

[20]  J. Chang-Claude,et al.  The patched polymorphism Pro1315Leu (C3944T) may modulate the association between use of oral contraceptives and breast cancer risk , 2003, International journal of cancer.

[21]  V. Zadnik,et al.  Oral Contraceptive Use and BRCA Penetrance: A Case-Only Study , 2009, Cancer Epidemiology Biomarkers & Prevention.

[22]  D Zeng,et al.  Maximum likelihood estimation of haplotype effects and haplotype‐environment interactions in association studies , 2005, Genetic epidemiology.

[23]  B. Ponder,et al.  Allele-Specific Up-Regulation of FGFR2 Increases Susceptibility to Breast Cancer , 2008, PLoS biology.

[24]  W. Willett,et al.  A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer , 2007, Nature Genetics.

[25]  B. Henderson,et al.  Risk factors for breast cancer in Chinese women in Shanghai. , 1988, Cancer research.

[26]  A. Sigurdsson,et al.  Common variants on chromosome 5p12 confer susceptibility to estrogen receptor–positive breast cancer , 2008, Nature Genetics.

[27]  J. Potter,et al.  Polymorphisms in Genes Involved in Sex Hormone Metabolism, Estrogen Plus Progestin Hormone Therapy Use, and Risk of Postmenopausal Breast Cancer , 2008, Cancer Epidemiology Biomarkers & Prevention.

[28]  M. Mohammadi,et al.  Structural basis for fibroblast growth factor receptor 2 activation in Apert syndrome , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Giske Ursin,et al.  FGFR2 variants and breast cancer risk: fine-scale mapping using African American studies and analysis of chromatin conformation. , 2009, Human molecular genetics.

[30]  A. Mueck,et al.  IARC monographs program on carcinogenicity of combined hormonal contraceptives and menopausal therapy , 2005, Climacteric : the journal of the International Menopause Society.

[31]  T. Sellers,et al.  Association of menstrual and reproductive factors with breast cancer risk: Results from the Shanghai breast cancer study , 2000, International journal of cancer.

[32]  Lester L. Peters,et al.  Genome-wide association study identifies novel breast cancer susceptibility loci , 2007, Nature.

[33]  T. Rebbeck,et al.  Hormone-dependent effects of FGFR2 and MAP3K1 in breast cancer susceptibility in a population-based sample of post-menopausal African-American and European-American women. , 2008, Carcinogenesis.

[34]  Peter Kraft,et al.  Heterogeneity of Breast Cancer Associations with Five Susceptibility Loci by Clinical and Pathological Characteristics , 2008, PLoS genetics.

[35]  James D. Yager,et al.  Chapter 3: Endogenous Estrogens as Carcinogens Through Metabolic Activation , 2000 .

[36]  J. Potter,et al.  Association of body size and fat distribution with risk of breast cancer among Chinese women , 2001, International journal of cancer.

[37]  Clifford A. Meyer,et al.  Genome-wide analysis of estrogen receptor binding sites , 2006, Nature Genetics.

[38]  Hongbing Shen,et al.  Genetic variants in fibroblast growth factor receptor 2 (FGFR2) contribute to susceptibility of breast cancer in Chinese women. , 2008, Carcinogenesis.

[39]  R. Langer,et al.  Influence of Estrogen Plus Progestin on Breast Cancer and Mammography in Healthy Postmenopausal Women: The Women's Health Initiative Randomized Trial , 2003 .

[40]  J. Klijn,et al.  Clinical correlates of low-risk variants in FGFR2, TNRC9, MAP3K1, LSP1 and 8q24 in a Dutch cohort of incident breast cancer cases , 2007, Breast Cancer Research.

[41]  Julian Peto,et al.  Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Collaborative Group on Hormonal Factors in Breast Cancer , 1996 .